|
|
|
|
| LEADER |
01750nam a2200325 u 4500 |
| 001 |
EB001865458 |
| 003 |
EBX01000000000000001029538 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190504 r ||| eng |
| 100 |
1 |
|
|a Banerjee, Srabani
|
| 245 |
0 |
0 |
|a Imiquimod for the treatment of basal cell or squamous cell carcinoma
|h Elektronische Ressource
|b a review of clinical effectiveness and cost-effectiveness
|c Srabani Banerjee, David Kaunelis
|
| 250 |
|
|
|a Version: 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c September 11, 2017, 2017
|
| 300 |
|
|
|a 1 PDF file (29 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Comparative Effectiveness Research
|
| 653 |
|
|
|a Carcinoma, Squamous Cell / drug therapy
|
| 653 |
|
|
|a Antineoplastic Agents
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Carcinoma, Basal Cell / drug therapy
|
| 653 |
|
|
|a Imiquimod / therapeutic use
|
| 700 |
1 |
|
|a Kaunelis, David
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK525601
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The purpose of this review is to compare the clinical effectiveness and cost-effectiveness of imiquimod (IMQ) to other treatment modalities for the treatment of basal cell carcinoma (BCC) or squamous cell carcinoma (SCC). This report is the first in the series of three reports on IMQ. The following two reports will be on actinic keratosis and genital warts
|